Abstract | PURPOSE: SETTING: Total of 94 patients enrolled in a randomized, double-blind, parallel-group and multicenter study. METHOD: Patients with NTG were randomly assigned to either Tafluprost or Placebo. Both ophthalmic solutions were instilled once a day in the morning for 4 weeks. RESULTS: Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001). IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo. A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions. CONCLUSION: These results indicate that Tafluprost is clinically useful in the treatment of NTG.
|
Authors | Yasuaki Kuwayama, Sadao Komemushi, Tafluprost Multi-center Study Group |
Journal | Nippon Ganka Gakkai zasshi
(Nippon Ganka Gakkai Zasshi)
Vol. 114
Issue 5
Pg. 436-43
(May 2010)
ISSN: 0029-0203 [Print] Japan |
PMID | 20545217
(Publication Type: Clinical Trial, Phase III, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Ophthalmic Solutions
- Prostaglandins F
- tafluprost
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Double-Blind Method
- Female
- Humans
- Intraocular Pressure
- Low Tension Glaucoma
(drug therapy, physiopathology)
- Male
- Middle Aged
- Ophthalmic Solutions
- Placebo Effect
- Prostaglandins F
(administration & dosage, adverse effects)
- Treatment Outcome
- Young Adult
|